In big pharma, leadership changes are rarely impulsive. They are signals. Sanofi’s decision not to renew Paul Hudson’s mandate as CEO marks a structural shift — not just for the company, but for how global pharma boards now evaluate performance. The headline isn’t simply succession.The headline is productivity. In 2026, ambition without measurable conversion is…





